The most prevalent genetic abnormalities identified in prostate cancer include point mutations in genes such as SPOP, FOXA1, and TP53, alongside copy number alterations (CNAs) affecting AR, MYC, RB1, PTEN, CHD1, and fusion genes associated with the ETS (E26 transformation-specific) family [26,30,31,32,33,34,35,36]. The gene discussed is MYC; the disease is prostate cancer.